A swelling top and bottom line spurs enthusiasm from Lars Kongsbak. The top line growth of 23 % in H1 is mainly powered by PCR products, for which the company outperforms the general market. The top chief has no reservations about calling it the company’s most important product range.
“We continue the trend we have witnessed for the latest many, many quarters now, and we are slowly breaking through the magic barrier. It’s not the first quarterly statement showing a positive EBITDA, but we can see that there’s a good foundation now,” says Lars Kongsbak in an interview with Medwatch.